Abstract:Objective To investigate the influence of dexmedetomidine on the neurotoxicity induced by sevoflurane in rats and the possible mechanisms. Methods Sixty seven-day-old male and female Sprague-Dawley rats weighing 15-20 g were randomly divided into normal saline group, dexmedetomidine group, sevoflurane group and dexmedetomidine plus sevoflurane group. The rats in the normal saline group and sevoflurane group were intraperitoneally given 10 μL normal saline and placed in a sealed box to inhale the mixed gas (30% O2+70% N2). The rats in the dexmedetomidine group and dexmedetomidine plus sevoflurane group were given dexmedetomidine (25 μg/kg, diluted with normal saline to 10 μL) intraperitoneally and placed in another sealed box to inhale the mixed gas containing 2% sevoflurane for 4 h. After 4 hours of disposition, 6 rats in each group were sacrificed to detect the expression of cleaved caspase-3 and p-p38 mitogen activated protein kinase (MAPK) in hippocampus by Western blotting. The rest rats were fed for 42 d, and the cognitive function was tested by Morris water maze. Results Compared with the normal saline group (0.069 4±0.090 0), the expression of cleaved caspase-3 in the sevoflurane group (0.137 3±0.200 0) was significantly increased (P<0.01). Compared with the sevoflurane group, the expression of cleaved caspase-3 in the dexmedetomidine plus sevoflurane group (0.095 8±0.130 0) was significantly decreased (P<0.05). Compared with the normal saline group (0.024 2±0.160 0), the expression of p-p38MAPK in the sevoflurane group (0.031 9±0.210 0) was significantly increased (P<0.05). Compared with the sevoflurane group, the expression of p-p38MAPK in the dexmedetomidine plus sevoflurane group (0.021 0±0.140 0) was significantly decreased (P<0.01). On day 45 and 46 of the experiment, the escape latency of the sevoflurane group was significantly prolonged compared with the normal saline group (both P<0.05), and the latency of the dexmedetomidine plus sevoflurane group was significantly shortened compared with the sevoflurane group (both P<0.05). Compared with the sevoflurane group (1.33±0.46), the frequencies of crossing the target platform in the normal saline group (3.44±0.51) and the dexmedetomidine plus sevoflurane group (1.89±0.86) were significantly increased (P<0.01 or 0.05). Conclusion Dexmedetomidine can decrease the neurotoxicity induced by sevoflurane during the development stage in rats, and p38MAPK may be involved in its mechanisms.

Dexmedetomidine Regulates Sevoflurane-Induced Neurotoxicity Through the Mir-330-3p/ulk1 Axis.

Dexmedetomidine Attenuates Neurotoxicity in Developing Rats Induced by Sevoflurane through Upregulating BDNF-TrkB-CREB and Downregulating ProBDNF-P75NRT-RhoA Signaling Pathway

Influence of dexmedetomidine on sevoflurane-induced neurotoxicity in development-stage rats

MicroRNA-325-3p prevents sevoflurane-induced learning and memory impairment by inhibiting Nupr1 and C/EBP/IGFBP5 signaling in rats

Dexmedetomidine Ameliorates the Neurotoxicity of Sevoflurane on the Immature Brain Through the BMP/SMAD Signaling Pathway

Dexmedetomidine Alleviates the Long-Term Neurodevelopmental Toxicity Induced by Sevoflurane in the Developing Brain

Dexmedetomidine Alleviates Brain Ischemia/Reperfusion Injury by Regulating Metastasis-associated Lung Adenocarcinoma Transcript 1/MicroRNA-140-5p/ Nuclear Factor Erythroid-derived 2-like 2 Axis

MiR-181a-5p knockdown ameliorates sevoflurane anesthesia-induced neuron injury via regulation of the DDX3X/Wnt/β-catenin signaling axis

Autophagy is Involved in Sevoflurane-Induced Developmental Neurotoxicity in the Developing Rat Brain

The impact of dexmedetomidine on ketamine‐induced neurotoxicity and cognitive impairment in young mice

Unraveling the signaling network between dysregulated microRNA and mRNA expression in sevoflurane-induced developmental neurotoxicity in rat

MicroRNA-214-5p involves in the protection effect of Dexmedetomidine against neurological injury in Alzheimer's disease via targeting the suppressor of zest 12

Dexmedetomidine Acts Via the JAK2/STAT3 Pathway to Attenuate Isoflurane-Induced Neurocognitive Deficits in Senile Mice

Dexmedetomidine inhibits microglial activation through SNHG14/HMGB1 pathway in spinal cord ischemia-reperfusion injury mice

Inhibition of miR-495-3p ameliorated sevoflurane induced damage through BDNF/ERK/CREB signaling pathways in HT22 cells

Dexmedetomidine Attenuates Isoflurane-Induced Cognitive Impairment Through Antioxidant, Anti-Inflammatory and Anti-Apoptosis in Aging Rat.

Microrna-181 Inhibitor Protects Against Sevoflurane-Induced Hippocampal Apoptosis And Memory Impairment

Dexmedetomidine Dose-Dependently Attenuates Ropivacaine-Induced Seizures and Negative Emotions Via Inhibiting Phosphorylation of Amygdala Extracellular Signal-Regulated Kinase in Mice

Dexmedetomidine inhibits neuronal apoptosis by inducing Sigma-1 receptor signaling in cerebral ischemia-reperfusion injury

Dexmedetomidine pretreatment alleviates ropivacaine-induced neurotoxicity via the miR-10b-5p/BDNF axis

Dexmedetomidine alleviates cognitive impairment by reducing blood-brain barrier interruption and neuroinflammation via regulating Th1/Th2/Th17 polarization in an experimental sepsis model of mice